Abstracts tagged "Dermatology"

Abstract Number: 2655 • ACR Convergence 2024
Diagnostic Challenges of Dermatomyositis: A Retrospective Study of Its Dermatologic Mimics and Misdiagnoses
Aaron Bao¹, Eleni Tiniakou², Lisa Christopher-Stine³, Christopher Mecoli³, Jemima Albayda¹, Julie Paik³, William Kelly⁴ and Jun Kang⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University, Lutherville Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Hillsboro, NH, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is often misdiagnosed due to its diverse clinical presentation. This study aimed to identify common dermatologic mimics of DM, characterize misdiagnosis rates…
Abstract Number: 0895 • ACR Convergence 2024
Procoagulant Extracellular Vesicles in Patients with Livedo Reticularis
Avital Baniel¹, Cristina Ricco², Rohan Dhiman³, Ahmed Eldaboush⁴, Caroline Stone⁴, Daniella Faden⁴, Luca Musante⁴, MIng-lin Liu⁴ and Victoria Werth⁵, ¹Perelman School of Medicine, UPENN, Philadelphia, PA, ²university of pennsylvania, Philadelphia, ³University of Pennsylvania, Newport Coast, CA, ⁴University of pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Procoagulant activity is an important property of EVs. Connective tissue disease (CTD) patients with livedo reticularis (LR) are known for their procoagulant conditions. The…
Abstract Number: 0930 • ACR Convergence 2024
The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts
Kaitlin Williams, Beita Badiei, Hana Minsky and Luis Garza, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses in intertriginous areas. Despite its increasing prevalence, the etiology…
Abstract Number: 0988 • ACR Convergence 2024
Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis
Yunjung Choi¹, Myeung-Su Lee² and Wan-Hee Yoo³, ¹Jeonbuk National University Medical School, Deokjin-gu, Jeollabuk-do, Republic of Korea, ²Wonkwang University Hospital, Iksan, South Korea, ³CHONBUK NATIONAL UNIVERSITY HOSPITAL, JEONJU, Republic of Korea
Background/Purpose: Cutaneous manifestations are common in rheumatic diseases and can be early indicators. This study investigates the prevalence of rheumatic diseases diagnosed through ANA (Antinuclear…
Abstract Number: 1062 • ACR Convergence 2024
Assessing Musculoskeletal Symptom Burden in a Cohort of Patients with Hidradenitis Suppurativa Using the IDEOM MSK-Q
Gretchen Ball¹, Hassan Hamade², Sarah Romanelli², Zachary Levy², Lourdes Perez Chada³, Joseph Merola⁴ and Alice Gottlieb⁵, ¹Albert Einstein College of Medicine, Ridgefield, CT, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁴UT Southwestern Medical Center, Newton, MA, ⁵Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA
Background/Purpose: Hidradenitis suppurativa (HS) has been associated with inflammatory joint diseases such as psoriatic arthritis and ankylosing spondylitis. Despite this correlation, dermatologists do not routinely…
Abstract Number: 1131 • ACR Convergence 2024
Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis
Vivian Laquer¹, Leon Kircik², Neil Sadick³, Jamie Weisman⁴, Yiwei Zhao⁵, Jessamyn Blau⁵, Wenwen Zhang⁶, Jonathan Uy⁵, Warren Winkelman⁶ and Melinda Gooderham⁷, ¹First OC Dermatology Research, Fountain Valley, CA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴Piedmont Atlanta, Atlanta, GA, ⁵Takeda Development Center Americas, Inc., Cambridge, MA, ⁶Takeda Development Center Americas, Inc., Cambridge, ⁷SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada
Background/Purpose: Zasocitinib (TAK-279) is a highly selective, allosteric, oral inhibitor of tyrosine kinase 2 (TYK2). TYK2 mediates signaling from cytokines involved in the pathogenesis of…
Abstract Number: 0955 • ACR Convergence 2023
GRB2 Serves as a Viable Target Against Skin Fibrosis in Systemic Sclerosis by Regulating Endothelial Cell Apoptosis
Yan Huang, Han Zhao, Xiangguang Shi, Jing Liu, Jui-Ming Lin, Qianqian Ma, Shuai Jiang, Weilin Pu, Yanyun Ma, Jianlan Liu, Wenyu Wu, Jiucun Wang and Qingmei Liu, Shanghai, Shanghai, China
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by vascular and immune system dysfunction, along with tissue fibrosis. Vascular damage has been recognized as…
Abstract Number: 1132 • ACR Convergence 2023
Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases
Wenhe Zhong, Jielian Lu, Dong Chen, Shiqun Zhang and Daiguo Deng, Guangzhou Fermion Technology Co., LTD, Guangzhou, China
Background/Purpose: Tyrosine Kinase 2 (TYK2) is a signaling protein within the Janus kinase (JAK) family. It plays a crucial role in transmitting signals from pro-inflammatory…
Abstract Number: 1210 • ACR Convergence 2023
Assessing Patient-Reported Drug Efficacy and Adherence Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis
Fahad Ahmed¹, Syed M. Rahman², Sarah Trent³, Lap Pham³, Nashwah Memon⁴, Hannah Chung³ and Adel Haque⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³PA Dermatology Partners, Philadelphia, PA, ⁴Lake Erie College of Osteopathic Medicine, Bradenton, FL, ⁵Jefferson Health - Northeast, Philadelphia, PA
Background/Purpose: Data suggest that patient satisfaction with drug therapy in psoriasis (Pso) and psoriatic arthritis (PsA) is associated with treatment compliance and, ultimately, disease response.…
Abstract Number: 1441 • ACR Convergence 2023
Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
Bruce Strober¹, Luis Puig², Andrew Blauvelt³, Diamant Thaçi⁴, Boni Elewski⁵, Maggie Wang⁶, Veerle Vanvoorden⁷, Delphine Deherder⁸, fabienne Staelens⁸, Susanne Wiegratz⁹, Joseph F. Merola¹⁰ and Carle Paul¹¹, ¹Yale University, New Haven, CT, ²Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ³Oregon Medical Research Center, Portland, OR, ⁴Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁵Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, ⁶UCB Pharma, Morrisville, NC, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Braine-l’Alleud, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Toulouse University and CHU, Toulouse, France
Background/Purpose: Clinical improvements through Week (Wk)96, with no unexpected safety findings, have previously been reported with bimekizumab (BKZ) in the BE RADIANT phase 3b trial…
Abstract Number: 1709 • ACR Convergence 2023
Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction
Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
Abstract Number: 2255 • ACR Convergence 2023
Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Kilian Eyerich¹, Alice B. Gottlieb², Stefano Piaserico³, Stefan Beissert⁴, Melinda Gooderham⁵, Brian Kirby⁶, Nicola Tilt⁷, Cynthia Madden⁸, Susanne Wiegratz⁹, Dirk de Cuyper¹⁰, Joseph F. Merola¹¹ and Boni Elewski¹², ¹Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Dermatology Unit, Department of Medicine, Università di Padova, Padova, Italy, ⁴Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, ⁵SKiN Centre for Dermatology, Probity Medical Research, Peterborough, ON, Canada, and Queen’s University, Kingston, ON, Canada, ⁶Elm Park and the Charles Institute, St Vincent's University Hospital, University College Dublin, Dublin, Ireland, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Morrisville, NC, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH
Background/Purpose: Psoriatic lesions in highly visible areas, including the nails, disproportionately affect patients' health‑related quality of life.[1] Here, we compare the efficacy of bimekizumab (BKZ)…
Abstract Number: 0055 • ACR Convergence 2023
Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses
Wenyan Miao¹, Daniel Rios¹, Mehrnaz Gharaee-Kermani², Craig Dobry², Artur Jaroszewicz¹, Cedric Arisdakessian¹, Enrique Garcia-Rivera¹, Nafeeza Hafeez¹, Brian Desrosiers¹, Jess Floro¹, Jared Steranka¹, Menachem Fromer¹, Dennis Zaller¹ and J. Michelle Kahlenberg², ¹Rome Therapeutics, Boston, MA, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) are retrotransposable DNA elements that make up ~17% of the human genome, and their role in health and disease is…
Abstract Number: 0085 • ACR Convergence 2023
Fibroblasts Promote Upregulation of Cannabinoid Type 2 Receptor on Inflammatory Cells in Dermatomyositis
DeAnna Diaz¹, Muhammad Bashir¹, Rohan Dhiman², Avital Baniel¹, Julianne Kleitsch¹, Rachita Pandya¹, Meena Sharma¹, Thomas Vazquez¹, Ming-Lin Liu², Mariko Momohara² and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. The activation of CB2R has been shown to reduce several,…
Abstract Number: 0336 • ACR Convergence 2023
Core Signs Associated with the Subtypes of Cutaneous Lupus Erythematosus: Concept Elicitation Interviews with Dermatologists and Rheumatologists
victoria werth¹, Annegret Kuhn², Joseph F. Merola³, Joerg Wenzel⁴, Cristina Vazquez-Mateo⁵, Sanjeev Roy⁶, Erik Thomas⁵, Oliver Guenther⁷, Ying Sun⁷, Alexandra Lauer⁷, Almary Guerra Rodriguez⁸, Patricia Koochaki⁹ and Paul Kamudoni⁷, ¹University of Pennsylvania, Wynnewood, PA, ²Amsterdam University Medical Center, Amsterdam, Netherlands, and University of Münster, Münster, Germany, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴University Hospital of Bonn, Bonn, Germany, ⁵EMD Serono, Billerica, MA, ⁶Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, ⁷the healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Laife Reply GmbH, Frankfurt am Main, Germany, ⁹ICON Clinical Research LLC, Raleigh, NC
Background/Purpose: Greater understanding of cutaneous signs and symptoms is needed to comprehensively define and measure cutaneous disease activity in lupus erythematosus. Herein, we interviewed dermatologic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].